The study data demonstrated that CF101 is efficacious in preventing the clinical manifestations of Anterior Uveitis in an animal model.
The study data support the utilization of CF101 as a drug candidate for the treatment of patients with Anterior or Posterior Uveitis and as such address a larger market than either alone, the company said.
OphthaliX interim CEO and chairman Pnina Fishman said the company is currently conducting all the preparatory work for a Phase 2 study in Uveitis in addition to the ongoing studies in Dry Eye Syndrome and Glaucoma.
"Although anterior uveitis is most often treated with topical medication, the excellent safety profile of CF101 suggests it could have a very favorable therapeutic index as a novel oral therapy in this disease," Fishman added.